A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia | MicrobiomeTrials← Back to trialsNCT06235801
A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2024-05-22Est. Completion: 2027-10-01
Enrollment target: 20 participants Locations- MD Anderson Cancer Center, Houston, Texas, United States
Other microbiome trials you might be interested in
Acute Myeloid Leukemia
The white blood cells of patients with acute myeloid leukemia that have undergone allogeneic stem cell transplantation w…
Freiburg im Breisgau, GermanyEst. completion May 30, 2027
Inherited Hematological DiseasesRare DiseasesFPDMM
Background:
Genes tell the body and its cells how to work. Familial platelet disease (FPD) or FPD with associated malig…
Bethesda, United StatesEst. completion Dec 31, 2028
Phase 3
Recruiting
Acute Myeloid LeukemiaRelapse/Recurrence
This is a multicenter, randomized, open-label, pragmatic low intervention clinical trial comparing high intensity reindu…
Brno, CzechiaEst. completion Jan 2028